Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
View Patent ↗This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1β (IL-1β)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation. Exemplary cytokine-mediated inflammatory conditions include, but are not limited to, local and systemic inflammation, inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatoid arthritis, asthma (including status asthmaticus), sepsis or septic shock, also including inflammatory skin conditions, for example, psoriasis and eczema.
1. A method for treating a cytokine-mediated inflammatory condition in a patient suffering therefrom, comprising:
administering to said patient an effective amount of a composition comprising an ester of an alpha-ketoalkanoic acid selected from the group consisting of alpha-ketopropionic acid (pyruvate), alpha-keto-butyrate, alpha-ketopentanoate, alpha-keto-3-methyl-butyrate, alpha-keto-4-methyl-pentanoate or alpha-keto-hexanoate in a pharmaceutically acceptable inert carrier substrate,
wherein the condition is selected from the group consisting of rheumatoid spondylitis, osteoarthritis, gouty arthritis, endotoxic shock, cerebral malaria, silicosis, pulmonary sarcoidosis, bone resorption disease, graft versus host disease, allograft rejections, fever and myalgia due to infection, AIDS related complex (ARC), Crohn's disease, rheumatoid arthritis, cachexia and septic shock.
2. The method of claim 1 , wherein said ester is an ester of pyruvic acid.
3. The method of claim 1 , wherein said carrier further includes a biologically safe component for inducing and stabilizing enolization of the alpha-keto functionality of said ester at physiological pH values.
4. The method of claim 3 , wherein said component for inducing and stabilizing enolization of the alpha-keto functionality of said ester is an inorganic, divalent cation.
5. The method of claim 4 , wherein said divalent cation is calcium or magnesium.
6. The method of claim 1 , wherein
said alpha-ketoalkanoic acid ester is ethyl pyruvate, and wherein
the composition further includes calcium, and
said inert carrier substance is Ringer's solution in a pH range of 7-8.
7. The method of claim 1 , wherein said inert carrier is a Ringer's solution of isotonic saline supplemented with potassium ion.
8. The method of claim 1 , wherein said ester of an alpha-ketoalkanoic acid compound is admixed in a saline solution, said solution containing a cation selected from the group consisting of calcium and magnesium.
9. A method for treating a cytokine-mediated inflammatory condition in a patient suffering therefrom, comprising:
administering to said patient an affective amount of a composition comprising an ester of an acid selected from the group consisting of alpha-keto-propionic acid (pyruvate), alpha-keto-butyrate, alpha-keto-pentanoate, alpha-keto-3-methyl-butyrate, alpha-keto-4-methyl-pentanoate and alpha-keto-hexanoate in a pharmaceutically acceptable inert carrier.
10. A method for treating a cytokine-mediated inflammatory condition in a patient suffering therefrom, comprising:
orally, intranasally, subcutaneously, intramuscularly, intravenously, intralumenally or intra-arterially administering to said patient an effective amount of a composition comprising an ester of an acid selected from the group consisting of ketopropionic acid (pyruvate), alpha-keto-butyrate, alpha-ketopentanoate, alpha-keto-3-methyl-butyrate, alpha-keto-4-methyl-pentanoate and alpha-keto-hexanoate, and, optionally, pharmaceutically safe organic or inorganic cations in a pharmaceutically acceptable inert carrier.
11. The method of claim 10 wherein the ester is an ethyl ester.
12. The method of claim 10 wherein the ester is ethyl pyruvate.
13. The method of claim 10 , wherein said composition is administered up to 24 hours after onset of said inflammatory condition.
14. The method of claim 10 , wherein said carrier further comprises a biologically safe component for inducing and stabilizing enolization of the alpha-keto functionality of said acid at physiological pH values.
15. The method of claim 14 , wherein said component for inducing and stabilizing enolization of the alpha-keto functionality of said ester is an inorganic, divalent cation.
16. The method of claim 15 , wherein said divalent cation is calcium or magnesium.
17. The method of claim 10 , wherein said inert carrier is Ringer's solution in a pH range of 7-8.
18. The method of claim 10 , wherein said inert carrier is a Ringer's solution of isotonic saline supplemented with potassium ion.
19. The method of claim 10 , wherein the ester is admixed in a saline solution, said solution containing a cation selected from the group consisting of calcium and magnesium.
20. The method of claim 10 , wherein said inflammatory condition is inflammatory bowel disease, rheumatoid arthritis, asthma, sepsis or septic shock.
21. A method for treating a cytokine-mediated inflammatory condition in a patient suffering therefrom, said method comprising:
administering to said patient an effective amount of a composition comprising ethyl pyruvate in a pharmaceutically acceptable inert carrier substance,
wherein the condition is selected from the group consisting of rheumatoid spondylitis, osteoarthritis, gouty arthritis, endotoxic shock, cerebral malaria, silicosis, pulmonary sarcoidosis, bone resorption disease, graft versus host disease, allograft rejections, fever and myalgia due to infection, AIDS related complex (ARC), Crohn's disease, rheumatoid arthritis, cachexia and septic shock.
22. A method for treating a cytokine-mediated inflammatory condition in a patient suffering therefrom, comprising:
administering to said patient an effective amount of a composition consisting essentially of an ester of an acid selected from the group consisting of ketopropionic acid (pyruvate), alpha-keto-butyrate, alpha-ketopentanoate, alpha-keto-3-methyl-butyrate, alpha-keto-4-methyl-pentanoate and alpha-keto-hexanoate, and, optionally, pharmaceutically safe organic or inorganic cations in a pharmaceutically acceptable inert carrier.
23. A method for treating a cytokine-mediated inflammatory condition in a patient suffering therefrom, comprising:
administering to said patient an effective amount of a composition consisting essentially of ethyl pyruvate in a pharmaceutically acceptable inert carrier.